Directory
>
Selda Samakoglu Md
Selda Samakoglu Md
Executive Director, Clinical Development, Oncology | Iovance Biotherapeutics, Inc.
Swampscott, Massachusetts, United States
Selda Samakoglu Md
Summary
Selda Samakoglu is an accomplished Executive Director in Clinical Development specializing in oncology, with extensive experience in pediatric hematology and oncology. With a Ph.D. in Molecular Biology and Medical Biology, she has a strong foundation in both scientific and clinical practices, enabling her to bridge the gap between research and commercial application. Selda has a proven track record in leading clinical programs, managing multi-million dollar budgets, and developing innovative strategies for drug and biologic therapies. Her leadership style is characterized by decisiveness and a collaborative approach, fostering a creative workplace. Selda is passionate about precision medicine and is known for her ability to translate complex scientific data into actionable business opportunities. She has built a robust network in the scientific and medical community, enhancing her impact on patient care and product commercialization. Selda's commitment to advancing clinical research is evident in her roles across various prestigious organizations, where she has consistently pushed the boundaries of cancer treatment.
Selda Samakoglu Md
Work Experience
Executive Director, Clinical Development, Oncology at
Iovance Biotherapeutics, Inc.
June 2021 - Present
Senior Director, Clinical Development, Oncology at
Replimune
May 2020 - June 2021
Director, Early Clinical and Translational Development at
CSL
November 2018 - May 2020
Director, Clinical and Translational Medicine, Lead of Hematology-Oncology Franchises at
Bristol Myers Squibb
May 2017 - November 2018
Director, Lead of Translational Medicine-Oncology at
Pharmacyclics, an AbbVie Company
September 2015 - May 2017
Director, Early Clinical and Translational Medicine Expert, Oncology at
Boehringer Ingelheim
April 2014 - August 2015
Senior Clinical Biomarker Lead of Biology-Biomarkers at
Gilead Sciences
June 2012 - February 2014
Principal Scientist, Head of pharmacodynamic biomarkers and mechanism of action group at
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
February 2010 - May 2012
Senior Scientist III at
ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company
February 2008 - February 2010
Assistant Professor at
Weill Cornel Medical College
January 2004 - February 2008
Principal Investigator at
Memorial Sloan Kettering Cancer Center
January 2002 - January 2007
Post Doctoral Research Fellow at
Institute Pasteur Paris
January 1999 - January 2002
Visiting Research Fellow at
Genethon Centre
January 2000 - January 2001
Selda Samakoglu Md
Education
Erasmus University School of Medicine in Rotterdam, Holland / Akdeniz University in Antalya, Turkey, Ph.D
January 1993 - January 1998
Hacettepe University in Ankara, Turkey / Mt Sinai School of Medicine, Md
Frequently Asked Questions about Selda Samakoglu Md
What is Selda Samakoglu Md email address?
Selda Samakoglu Md's primary email address is ***************@iovance.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Selda Samakoglu Md work for?
Selda Samakoglu Md is a Executive Director, Clinical Development, Oncology at Iovance Biotherapeutics, Inc., a company specializing in Commercial physical research.
Where Selda Samakoglu Md graduated from?
Selda Samakoglu Md holds a degree in Molecular Biology And Medical Biology from Erasmus University School of Medicine in Rotterdam, Holland / Akdeniz University in Antalya, Turkey.
How can I directly contact Selda Samakoglu Md?
To contact Selda Samakoglu Md directly, you can use the email address ***************@iovance.com. Complete contact information is available upon registration with Muraena.
Is Selda Samakoglu Md an immigrant?
Yes, Selda Samakoglu Md is an immigrant and currently based in United States
Who is Selda Samakoglu Md?
Selda Samakoglu is an accomplished Executive Director in Clinical Development specializing in oncology, with extensive experience in pediatric hematology and oncology. With a Ph.D. in Molecular Biology and Medical Biology, she has a strong foundation in both scientific and clinical practices, enabling her to bridge the gap between research and commercial application. Selda has a proven track record in leading clinical programs, managing multi-million dollar budgets, and developing innovative strategies for drug and biologic therapies. Her leadership style is characterized by decisiveness and a collaborative approach, fostering a creative workplace. Selda is passionate about precision medicine and is known for her ability to translate complex scientific data into actionable business opportunities. She has built a robust network in the scientific and medical community, enhancing her impact on patient care and product commercialization. Selda's commitment to advancing clinical research is evident in her roles across various prestigious organizations, where she has consistently pushed the boundaries of cancer treatment.
Selda`s contact details
***************@iovance.com
***************@replimune.com
Colleagues
Vice President, Cell Therapy Account Teams
Senior Vice President, Medical Affairs
Vice President, Research Alliances
Interim CEO and General Counsel
Chief Medical Officer
Executive Director
SVP Head of Digital and Information Technology
Vice President, Regulatory Affairs
Executive Director, CMC Biostatistics
VP, Global Commercial Operations